Biosion
Dr. Chen is the CEO of Biosion, Inc. Before establishing Biosion, Dr. Chen served as Senior Director of Monoclonal Antibody Operations at SDIX, Inc., where he led the team responsible for innovative antibody discovery services for biotech and pharmaceutical companies. Dr. Chen joined SDIX from Abbott Laboratories (now AbbVie), where he made critical contributions to several innovative biologic programs including ABT165 (now in Phase-II). Dr. Chen has over 20 years of antibody development experience in the biotech and pharmaceutic industries with expertise in competitive innovative discovery and preclinical development.
Dr. Chen received his Ph.D. degree in Molecular Medicine from the University of Texas Health Science Center at San Antonio.
Biosion
Biosion is a leading “In Global For Global” clinical stage biotechnology company developing innovative biologics to address resistant, relapsed and residual disease for patients worldwide.